The impact of immune dysregulation on the risk of malignancy in common variable immunodeficiency: insights from a multicenter studyMarta Dafne Cabañero-Navalón, Pedro Moral, J.L. Patier de la Peña et al.|Frontiers in Immunology|2024Cited by 11
Real-world patterns of immunoglobulin replacement therapy for infection prevention in common variable immunodeficiency: a multicenter nationwide studyPedro Moral, Marta Dafne Cabañero-Navalón, Arnau Antolí et al.|Frontiers in Immunology|2025Cited by 5
Immunologic biomarkers of noninfectious complications and overall survival in common variable immunodeficiencyAlba Torres‐Valle, Alberto Órfão, Filomeen Haerynck et al.|Journal of Allergy and Clinical Immunology|2025Cited by 5
Linking Microbiota Profiles to Disease Characterization in Common Variable Immunodeficiency: The Case of Granulomatous–Lymphocytic Interstitial Lung DiseaseMarta Dafne Cabañero-Navalón, Víctor García-Bustos, Pedro Moral et al.|Biomedicines|2024Cited by 4
Infectious outcomes of a standardized subcutaneous immunoglobulin dose reduction strategy in primary immune deficiencies amid global shortagePedro Moral, Víctor García-Bustos, Héctor Balastegui-Martín et al.|Frontiers in Immunology|2025Cited by 4